VISUGLICAN COLL 25D 40+2MG/ML

VISUGLICAN 40MG/ML + 2MG/ML COLLIRIO, DEOLUTION

active ingredients

100 ml of colliery, solution contain: Active ingredients: Sodium Chromoglycato 4 g; Clorfenamina maleate 0.2 g. For the complete list of excipients, see paragraph 6.1

Excellent

Visuglican Collirio, 10 ml bottle solution: 100 ml of colliery contain: Sodium edetate; Phosphate bishodic; Monosodium phosphate; Purified water. Visuglican Collirio, solution in monodose containers: 100 ml of colliery contain: Sodium edetate; Phosphate bishodic; Monosodium phosphate; Water for injectable preparations.

Therapeutic indications

Treatment of toxic, allergic and spring conjunctivitis, subacute and chronic.

Contraindications

Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1.

Population

1-2 drops in the joint furnace four times a day. Before use make sure that the single-dose container is intact. Visuglican in monodose container should only be used immediately after opening. Any residue must not be used. Avoid the end of the container to contact the eye or any other surface.

Conservation

Flacone: Store at a temperature not exceeding 25°C. Monodose: keep the product away from heat sources.

Warnings

To be used under the direct control of the doctor. Do not use if the solution is not clear. Visuglican 10 ml bottle contains phosphate 6,50 mg per 1 ml equivalent to 65 mg/10 ml, and phosphate monosodium 2 mg per 1 ml equivalent to 20 mg/10 ml. Visuglican monodose contains phosphate 8,12 mg per 1 ml equivalent to 4,06 mg/0,5 ml and monosodium phosphate 4,5 mg per 1 ml.

Interactions

There are no known interactions with other drugs. However additive effects are possible when Visuglican is administered simultaneously to H₂ antagonists (cymetidine) and corticosteroids.

Effects

Rarely, irritative and burning phenomena have been reported. In such cases it is advisable to suspend treatment. (see paragraph 4.3) Very rarely have been reported cases of cornea calcification associated with the use of phosphates in patients with significantly damaged cornea. Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: https://www.aifa.gov.it/web/guest/content/segnalazioni-reazioni-avverse.

Overdosing

Overdose phenomena have not been reported.

As for each drug it is appropriate, when possible, to avoid administration during the first trimester of pregnancy. If the use of this product is considered essential in a nursing mother, the patient must suspend breastfeeding.

Source: Farmadati